KRTX Karuna Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRTX

Price (delayed)

$191.63

Market cap

$6.61B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.74

Enterprise value

$6.36B

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and ...

Highlights
The company's quick ratio rose by 35% YoY and by 13% QoQ
The debt has declined by 29% year-on-year and by 9% since the previous quarter
The equity has surged by 124% year-on-year but it has declined by 4.9% since the previous quarter
The net income has plunged by 92% YoY and by 21% from the previous quarter
KRTX's EPS has dropped by 77% year-on-year and by 17% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://karunatx.com
Peers: OVID

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
34.47M
Market cap
$6.61B
Enterprise value
$6.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.85
Price to sales (P/S)
569.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
598.19
Earnings
Revenue
$10.64M
EBIT
-$274.92M
EBITDA
-$273.81M
Free cash flow
-$228.92M
Per share
EPS
-$8.74
Free cash flow per share
-$7.24
Book value per share
$32.77
Revenue per share
$0.34
TBVPS
$36.78
Balance sheet
Total assets
$1.16B
Total liabilities
$37.1M
Debt
$5.33M
Equity
$1.13B
Working capital
$1.12B
Liquidity
Debt to equity
0
Current ratio
34.02
Quick ratio
33.12
Net debt/EBITDA
0.89
Margins
EBITDA margin
-2,574.1%
Gross margin
100%
Net margin
-2,597.9%
Operating margin
-2,723.3%
Efficiency
Return on assets
-33.5%
Return on equity
-34.9%
Return on invested capital
-54.4%
Return on capital employed
-24.3%
Return on sales
-2,584.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
1.21%
1 week
7.01%
1 month
-2.91%
1 year
68.57%
YTD
-2.48%
QTD
-2.48%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$10.64M
Gross profit
$10.64M
Operating income
-$289.68M
Net income
-$276.34M
Gross margin
100%
Net margin
-2,597.9%
The operating income has dropped by 101% year-on-year and by 24% since the previous quarter
The net income has plunged by 92% YoY and by 21% from the previous quarter
The company's revenue has shrunk by 75% QoQ and by 71% YoY
The company's gross profit has shrunk by 75% QoQ and by 71% YoY

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
5.85
P/S
569.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
598.19
KRTX's EPS has dropped by 77% year-on-year and by 17% since the previous quarter
The equity has surged by 124% year-on-year but it has declined by 4.9% since the previous quarter
The price to book (P/B) is 20% less than the last 4 quarters average of 7.3
The price to sales (P/S) is 140% more than the last 4 quarters average of 237.0
The company's revenue has shrunk by 75% QoQ and by 71% YoY

Efficiency

How efficient is Karuna Therapeutics business performance
Karuna Therapeutics's return on equity has decreased by 31% YoY but it has increased by 2.5% QoQ
The return on assets has declined by 30% year-on-year but it is up by 2% since the previous quarter
Karuna Therapeutics's ROIC has increased by 14% from the previous quarter

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
The total assets has surged by 120% year-on-year but it has declined by 5% since the previous quarter
KRTX's total liabilities is up by 45% YoY but it is down by 17% from the previous quarter
The debt is 100% smaller than the equity
The equity has surged by 124% year-on-year but it has declined by 4.9% since the previous quarter
The debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.